Last reviewed · How we verify
0,1% sodium hyaluronate
At a glance
| Generic name | 0,1% sodium hyaluronate |
|---|---|
| Also known as | Hyabak |
| Sponsor | Hospital de La Luz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influence of Hyaluronic Acid in the Healing of Palatal Donor Sites During Free Gingival Graft Procedures (NA)
- Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis (NA)
- Effect of Injectable Hyaluronic Acid (HYADENT BG (HA)) on Bone Healing in Extraction Sockets (NA)
- Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain (PHASE3)
- Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles (NA)
- Bridging Technique Validation for Nasolabial Folds JN-BRIDGE-1 (NA)
- Clinical Study to Investigate a New Mouthwash in Reducing Plaque and Helping Prevent Gum Problems on Dental Implants Over a 6-month Period of Product Use (PHASE3)
- Clinical Performance and Safety of STYLAGE® HydroMax (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0,1% sodium hyaluronate CI brief — competitive landscape report
- 0,1% sodium hyaluronate updates RSS · CI watch RSS
- Hospital de La Luz portfolio CI